Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — Shareholder Meeting (November 2022)
8 slides from Emvision Medical Devices's shareholder meeting presentation, Nov 16, 2022
Slide 1: AGM Chairman's Address & Presentation
16/11/22 EMvision Medical Devices Ltd ACN 620 388 230 Level 10, 12 Creek Street, Brisbane Qld 4000 02 8667 5337 contact@emvision.com.au AGM CHAIRMAN’S ADDRESS & PRESENTATION EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”), is pleased to provide the following Chairman’s addr
Slide 2: Chairman's Address Conclusion and About EMVision
To conclude, I’d like to thank our shareholders for supporting our Company, my fellow Directors and the wonderful team at EMVision. I will now move to the formal part of the meeting. Authorised for release by the Board of the Company. [ENDS] For further information, media or investor enquiries, plea
Slide 3: AGM 2022 CEO Presentation
www.emvision.com.au AGM 2022 CEO PRESENTATION Point-of-Care electromagnetic imaging to revolutionise stroke diagnosis and monitoring NOVEMBER 2022 ASX:EMV
Slide 4: 2022 Highlights
2022 HIGHLIGHTS EMBARKING ON MULTI- Trial commencing at leading stroke centers across NSW, VIC and QLD, EMVISION HAS CONTINUED TO PURSUE CENTRE TRIAL pre-validation and validation phases intended to support first regulatory COMPLEMENTARY NON-DILUTIVE GRANT submissions FUNDING OPPORTUNITIES TO ACCELE
Slide 5: US Market Assessment and Insights
US MARKET ASSESSMENT AND INSIGHTS Research conducted by IDR Medical, a leading international medical market research and consulting firm Number of beds To assess the opportunity for EMVision’s brain imaging PROJECT GOAL system in the management of stroke & advance US 5% market entry strategy 8% 20%
Slide 6: US Market Assessment and Insights – Overall Response
US MARKET ASSESSMENT AND INSIGHTS – OVERALL RESPONSE The ability to use 1st Gen for post-intervention/treatment monitoring was a highly rated potential benefit Key value drivers/ benefits of 1st Gen Most 1. Optimal solution for ▪ Portability, ease of use, & non-ionizing radiation enables the device
Slide 7: US Market Respondent Feedback on 1st Gen Device
US MARKET RESPONDENT FEEDBACK ON 1ST GEN DEVICE Commentary from stroke care respondents on use cases in a tertiary hospital setting, remote areas and anticipated scan volumes Will be used much more often We do way more than 5 scans a day. On the ICU we are monitoring patients every day and POC for r
Slide 8: Set Up for Success
05 www.manjur.com SET UP FOR SUCCESS • We have assembled a team of medtech experts that have successfully done this before • We have compelling support from the leading minds in stroke care • Globally there is an increasing demand for Point-of-Care imaging solutions • Multi-billion-dollar market opp
Emvision Medical Devices — Shareholder Meeting (November 2022) on 6ix